Skip to content

Study · Animal study (in vivo) · 2000

3 results

Interactions of IGF-1 with the blood-brain barrier in vivo and in situ.

Pan W, Kastin AJ

Neuroendocrinology1 Sept 2000Cited by 118 (Europe PMC)

PMID11025411 (opens in a new tab)DOI10.1159/000054584 (opens in a new tab)PepBankPUB-11025411
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In the in vivo study, des(1‑3)IGF-1 had a shorter blood half-life than IGF-1.

    In plain wordsIn animals, des(1‑3)IGF-1 remained in blood for less time than IGF-1.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseBlood half-life
    Study

    n: not reported in source

    Comparator
    IGF-1
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    By contrast, des(1-3)IGF-1, an IGF-1 analogue with little protein binding but similar biological activity, had a shorter half-life in blood, slower influx rate into brain, and no alteration in pharmacokinetics after addition of nonradiolabeled peptide.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In the in vivo study, des(1‑3)IGF-1 entered the brain more slowly than IGF-1.

    In plain wordsIn animals, des(1‑3)IGF-1 entered the brain more slowly than IGF-1.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseBrain influx rate
    Study

    n: not reported in source

    Comparator
    IGF-1
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    By contrast, des(1-3)IGF-1, an IGF-1 analogue with little protein binding but similar biological activity, had a shorter half-life in blood, slower influx rate into brain, and no alteration in pharmacokinetics after addition of nonradiolabeled peptide.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    Adding nonradiolabeled peptide did not alter des(1‑3)IGF-1 pharmacokinetics in the study.

    In plain wordsIn animals, adding unlabeled peptide did not change des(1‑3)IGF-1 movement through the body.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changePharmacokinetics with unlabeled peptide
    Study

    n: not reported in source

    Comparator
    without added nonradiolabeled peptide
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    By contrast, des(1-3)IGF-1, an IGF-1 analogue with little protein binding but similar biological activity, had a shorter half-life in blood, slower influx rate into brain, and no alteration in pharmacokinetics after addition of nonradiolabeled peptide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.